July 30, 2026

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL

Sub: Outcome of Board Meeting of ANLON HEALTHCARE LIMITED ("Company")

Respected Sir/Madam,

Pursuant to Regulation 30 read with Part - A of Schedule III of SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Thursday, July 30, 2026 at the Registered Office of the Company *inter alia* considered and approved the following matters:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company as set out in compliance with Indian Accounting Standards ("IND AS") for the quarter ended June 30, 2026; together with the Limited Review Report of the Auditor's thereon. (Enclosed herewith)

2. the Board authorized to Mr. Punitkumar Rasadia, Chairman & Managing Director and/or Mr. Meet Vachhani, Whole Time Director of the Company, for entering into a share swap arrangement with the shareholders of Apiqo Organics Private Limited ("AOPL") and Bizotic LifeScience Private Limited ("BLPL") to acquire [32.52%] shareholding in AOPL and [43.33%] shareholding in BLPL, to make both these entities as wholly owned subsidiaries, in lieu of issuance and allotment of the fresh equity shares of the Company on a preferential basis for consideration other than cash, to such selling shareholders.

Meeting Commenced on 10:30 a.m. IST and Concluded on 11:30 a.m. IST.

You are requested to take the above information on your record.

Thanking You.
For ANLON HEALTHCARE LIMITED

Rasadia
Punitkumar
Rameshbhai

Digitally signed by Rasadia Punitkumar Rameshbhai
DN: c=IN, o=Personal, title=4798,
pseudonym=1336344036629247286lWAue1dglYlP1,
2.5.4.20=a003a5c41c134976122eef293c4077137aa4a1ecd74ed223ac0e8dcc8264a5a2, postalCode=360005,
st=Gujarat,
serialNumber=9067d666c809e74b4abe895e7d3c841cee4ae962d432d246758d2cb6b96167f3, cn=Rasadia Punitkumar Rameshbhai
Date: 2026.07.30 11:40:55 +05'30'

PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Anlon Healthcare Limited

(1) We have reviewed the accompanying statement of unaudited standalone financial results of Anlon Healthcare Limited (the 'Company') for the quarter ended June 30, 2026 and year to date from April 01, 2026 to June 30, 2026 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').

(2) This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

(3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

(4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, R V D & Co
Chartered Accountants
ICAI Firm Registration No 143936W

R V D & Co. FRN: 143936W M.No.: 174550 City: Rajkot Chartered Accountants

Kaushal V. Dave
(Partner)
Membership No 174550
UDIN: 26174550EWYOOU7762

Date: July 30, 2026
Place: Rajkot

"Level-6",Office No 604-605,Near AP Park, Opp Imperial Heights, Rajkot-360005
+91 6356 797 885 0281 - 2991685 office@cakda.in www.cakda.in

Anlon Healthcare Limited

L24230GJ2013PLC077543

Address: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road,Rajkot 360005, Gujarat (INDIA)

Standalone Financial Result for the period ended on 30-6-2026

Rs. in Lakhs (Unless stated otherwise)

Sr No	Particulars	Quarter Ended			Year Ended
		30-6-2026	31-3-2026	30-6-2025	31 March 2026
		Unaudited	Audited	Unaudited	Audited
I	Income				
	Revenue From Operations	3,097.56	5,542.22	3,329.72	17,649.87
	Other Income	5.96	1.25	1.17	25.39
	Total Income (I)	3,103.52	5,543.47	3,330.89	17,675.26
II	Expenses				
	Cost of materials consumed	2,694.05	3,323.68	2,959.48	12,976.38
	Changes in inventories of finished goods, Stock in Trade and work in	-789.16	235.76	-537.18	-1,691.69
	Employee benefits expense	152.07	125.16	122.49	525.12
	Finance costs	96.36	118.29	82.05	435.29
	Depreciation and amortization expense	65.79	13.09	42.68	136.31
	Other expenses	294.04	466.34	160.96	1,226.28
	Total expenses (II)	2,513.15	4,282.32	2,830.48	13,607.69
III	Profit/(loss) before tax (I-II)	590.37	1,261.15	500.41	4,067.57
IV	Tax expenses				
	Current tax	152.39	148.54	147.91	1,140.03
	Deferred tax	-41.73	133.41	-2.19	146.72
	Total Tax expense (IV)	110.66	281.95	145.72	1,286.75
V	Profit/(loss) after tax for the period (III-IV)	479.71	979.20	354.69	2,780.82
VI	**Other Comprehensive Income**				
	OCI that will not be reclassified to P&L	-2.31	-7.13	-	-6.79
	OCI Income tax of items that will not be reclassified to P&L	0.58	1.70	-	1.70
	Total Other Comprehensive Income (VI)	-1.73	-5.43	-	-5.09
VII	Total Comprehensive Income for the period (V+VI)	477.98	973.77	354.69	2,775.73
VIII	Earnings per equity share				
	Basic	0.09	0.21	0.09	0.59
	Diluted	0.09	0.21	0.09	0.59

For and on behalf of Board of Directors,
Anlon Healthcare Limited

Anlon Healthcare Ltd.

Punitkumar R. Rasadia
Managing Director

Place: Rajkot
Date: July 30, 2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date 30/07/2026
Place : Rajkot

Anlon Healthcare Limited
L24230GJ2013PLC077543
Notes to the Standalone Financial Result for the period ended on 30-6-2026

1 Corporate information

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

2 Basis of Preparation

The Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The standalone financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The standalone financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

3 Segment Reporing

Anlon Healthcare Limited is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

4 The Status of investor complaints received by the company is as follows :

During Quarter 1 of FY 2026-27, the Company did not receive any complaints from investors. Accordingly, there were no pending investor complaints as on the end of the quarter.

5 List of Group Companies or Subsidiary company

Bizotic Lifescience Private Limited.
Apiqo Organics Private Limited.
Remember India Health links Private Limited.

6 The above financial results of Anlon Healthcare Limited (the "Company") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on July 30, 2026, respectively

7 The figures for the previous periods have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current period's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current period's financial statements.

8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel,Packing Material,Factory Electricity Expenses,Freight Inward,Advertisement Expenses,Canteen and -Import Duty Expenses Etc

For and on behalf of Board of Directors,
Anlon Healthcare Limited

Anlon Healthcare Ltd

Punitkumar R. Rasadia
Managing Director

Place: Rajkot
Date: July 30, 2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date. 30 / 07 / 2026
Place : Rajkot

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Anlon Healthcare Limited

(1) We have reviewed the accompanying statement of unaudited Consolidated financial results of Anlon Healthcare Limited (the 'Company') for the quarter ended June 30, 2026 and year to date from April 01, 2026 to June 30, 2026 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').

(2) This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

(3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

(4) The Statement includes the interim financial results of the following entities:

Name of the Entity	Relationship
Anlon Healthcare Limited	Holding Company
Apiqo Organics Private Limited	Subsidiary Company
Bizotic Lifescience Private Limited	Subsidiary Company
Remember India Health Links Private Limited	Subsidiary Company

R V D & Co. FRN : 143936W M.No. : 174550 City : Rajkot Chartered Accountants

Other Matters

(5) The Statement includes the unaudited interim financial results and other unaudited financial information, in respect of:

(i) 3 (Three) subsidiaries, whose unaudited interim financial results and other unaudited financial information include total revenue (before consolidation adjustments) of ₹5707.14 lakhs, total net Profit after tax (before consolidation adjustments) of ₹348.42 lakhs, total comprehensive Profit (before consolidation adjustments) of ₹348.26 lakhs for the quarter ended June 30, 2026, as considered in the Statement. These unaudited financial results and financial information have been approved and furnished to us by the Management of the Holding Company and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on such unaudited financial results and financial information.

For, R V D & Co
Chartered Accountants
ICAI Firm Registration No 143936W

R V D & Co.
FRN : 143936W
M.No. : 174550
City : Rajkot
Chartered Accountants

Kaushal V. Dave
(Partner)
Membership No 174550
UDIN: 26174550FQEVQR8840

Date: July 30, 2026
Place: Rajkot

Anlon Healthcare Limited

L24230GJ2013PLC077543

Address: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road,

Consolidated Financial Result for the period ended on 30-06-2026

Rs. in Lakhs (Unless stated otherwise)

Sr No	Particulars	Quarter Ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31 March 2026
		Unudited	Audited	Unaudited	Audited
I	**Income**				
	Revenue From Operations	8,756.27	5,088.91	3,329.72	17,196.56
	Other Income	5.96	1.40	1.17	25.54
	Total Income (I)	8,762.23	5,090.31	3,330.89	17,222.10
II	**Expenses**				
	Cost of materials consumed	7,303.61	5,278.25	2,959.48	14,930.95
	Changes in inventories of finished goods, Stock in Trade and work in	-695.55	-2,493.40	-537.18	-4,420.85
	Employee benefits expense	194.65	154.08	122.49	554.04
	Finance costs	92.46	57.07	82.05	374.07
	Depreciation and amortization expense	106.60	29.19	42.68	152.41
	Other expenses	394.47	620.82	160.96	1,380.76
	Total expenses (II)	7,396.24	3,646.01	2,830.48	12,971.38
III	**Profit/(loss) before tax (I-II)**	1,365.99	1,444.30	500.41	4,250.72
IV	Tax expenses				
	Current tax	349.30	188.78	147.91	1,180.27
	Deferred tax	188.55	148.33	-2.19	161.64
	Total Tax expense (IV)	537.85	337.11	145.72	1,341.91
V	**Profit/(loss) after tax for the period (III-IV)**	828.14	1,107.19	354.69	2,908.81
VI	**Other Comprehensive Income**				
	OCI that will not be reclassified to P&L	-2.52	-7.13	-	-6.79
	OCI Income tax of items that will not be reclassified to P&L	0.63	1.70	-	1.70
	Total Other Comprehensive Income (VI)	-1.89	-5.43	-	-5.09
VII	**Total Comprehensive Income for the period (V+VI)**	826.25	1,101.76	354.69	2,903.72
VIII	**Profit/(loss) after tax for the period (III-IV) attributable to:**				
	-Owners of the company	666.21	1,049.76	354.69	2,851.38
	-Non-Controlling Interests	161.93	57.43	-	57.43
		828.14	1,107.19	354.69	2,908.81
IX	**Total Other Comprehensive Income (VI) attributable to:**				
	-Owners of the company	-1.89	-5.43	-	-5.09
	-Non-Controlling Interests	-	-	-	-
		-1.89	-5.43	-	-5.09
X	**Total Comprehensive Income for the period (V+VI) attributable to:**				
	-Owners of the company	664.32	1,044.34	354.69	2,846.29
	-Non-Controlling Interests	161.93	57.43	-	57.43
		826.25	1,101.77	354.69	2,903.72
XI	**Details of Equity Share Capital**				
	Paid-Up Equity Share Capital	1,063,030,000.00	531,515,000.00	398,515,000.00	531,515,000.00
	Face Value of Equity Share Capital (Per Value)	2.00	10.00	10.00	10.00
	Other Equity				
XII	**Earnings per equity share**				
	Basic	0.16	0.23	0.09	0.61
	Diluted	0.16	0.23	0.09	0.61

For and on behalf of Board of Directors,
Anlon Healthcare Limited

Punitkumar R. Rasadia
Managing Director

Place: Rajkot
Date: July 30, 2026

Anlon Healthcare Ltd

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date 30/07/2026
Place : Rajkot

Anlon Healthcare Limited
L24230GJ2013PLC077543
Notes to the Consolidated Financial Result for the period ended on 30-06-2026

1 Corporate information

The consolidated financial statements comprise financial statements of Anlon Healthcare Limited (the "Company") and its subsidiaries (collectively the "Group") for the period ended June 30, 2026

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

2 Basis of Preparation

The Consolidated Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The Consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The Consolidated financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

3 Segment Reporing

Anlon Healthcare Limited and its Subsidiaries is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

4 The Status of investor complaints received by the company is as follows :

During Quarter 1 of FY 2026-27, the Company did not receive any complaints from investors. Accordingly, there were no pending investor complaints as on the end of the quarter.

5 List of Group Companies or Subsidiary company

Bizotic Lifescience Private Limited.
Apiqo Organics Private Limited.
Remember India Health links Private Limited.

6 The figures for the previous periods have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current period's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current period's financial statements.

7 Other Expenses includes operational, statutory, and administrative expenses Power Fuel,Packing Material,Factory Electricity Expenses,Freight Inward,Advertisement Expenses,Canteen and -Import Duty Expenses Etc

For and on behalf of Board of Directors,
Anlon Healthcare Limited

Anlon Healthcare Ltd

Punitkumar R. Rasadia
Managing Director

Place: Rajkot
Date: July 30, 2026

SIGNED FOR IDENTIFICATION BY
R V D & Co.
Chartered Accountants
FRN 143936W

Date 30/07/2026
Place : Rajkot

To
The Board of Directors,
Anlon Healthcare Limited
101/102, Silver Coin Complex,
Opp. Crystal Mall,
Rajkot-360005

Statutory Auditor's Certificate certifying utilization of the Gross/Net offer proceeds received consequent to the issue of equity shares through the Initial Public Offer ("IPO")/ Qualified Institutional Placement (QIP)/ Right Issue (RI)/ Preferential issue (PI) during the quarter ended June 30, 2026.

1. This certificate is issued in accordance with the terms of our appointment letter dated May 01,2026.

2. We R V D & Co, Chartered Accountants (Firms' Registration No: 143936W), the statutory auditors of Anlon Healthcare Limited, having its registered office at 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360006 have examined the unaudited books of account for the period from April 01, 2026 to June 30, 2026 to certify if the utilization of the Gross/Net offer proceeds received through the IPO (as applicable) for the quarter ended June 30, 2026 (included in "Annexure A") is in agreement with the unaudited books of account and in accordance with the terms of utilization included in the Prospectus to the IPO.

Management's Responsibility for the Statement

3. Management of the Company is responsible for the appropriate utilization of funds for objects stated in the Letter of offer of the Company.

4. The Management of the Company is also responsible for the adherence to the provisions of the Companies Act, 2013 and all the applicable guidelines/ regulations specified by the Securities and Exchange Board of India ("SEBI"), the Ministry of Corporate Affairs ("MCA").

Auditor's Responsibility

5. Our responsibility is to provide limited assurance on whether the payments made representing the utilization of the Gross/Net proceeds of the IPO) is in agreement with the unaudited books of account and in accordance with the purposes mentioned in the Prospectus to the IPO. Nothing contained in this Certificate, nor anything said or done in the course of, or in connection with the services that are subject to this Certificate, will extend to any duty of care that we may have in our capacity of the statutory auditors of any financial statements of the Company.

6. We have conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the Institute of Chartered Accountants of India ("ICAI") and Standards on Auditing specified under Section 143(10) of the Companies Act, 2013. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by ICAI. The procedures performed vary in nature and timing from, and are less extent than for, a reasonable assurance. Consequently, the level of assurance obtained is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

7. We have neither performed an audit nor a review in accordance with the generally accepted auditing standards in India and accordingly we do not express any opinion on the contents of the Statement. Had we performed additional procedures in accordance with the generally accepted standards on auditing in India, other matters might have come to our attention that would have been reported.

R V D & Co.
FRN : 143936W
M.No. : 174550
City : Rajkot
Chartered Accountants

8. Accordingly, we have performed the following procedures in relation to the Statement:

   a) Obtained and read the "Statement" for the period from April 01, 2026 to June 30, 2026.
   b) Traced the "Amount as proposed in the Offer Document" from the Prospectus date
   c) Traced the Initial Public Offer proceeds from the bank statement.
   d) Verified the utilization with the supporting documents and other records including the entries in the unaudited books of account of the Company for the period from April 01, 2026 to June 30, 2026.
   e) Made necessary inquiries with the management and obtained relevant representations in respect of matters relating to the Statement.
   f) We have been provided with Bank Statements, Minutes of Meeting of Shareholders, Minutes of Board Meeting.

9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements as issued by ICAI.

Conclusion

10. Based on our examination, as referred above, and the information and explanations provided to us by the Management of the Company, nothing has come to our attention that causes us to believe that the utilization of the Gross/Net proceeds during the period April 01, 2026 to June 30, 2026 arising from the Company's IPO read with and subject to the notes thereon (included in "Annexure A"), are not in agreement with the unaudited books of account of the Company or have not been used for the purposes as mentioned in the Prospectus to the IPO.

Restriction on Use

11. This certificate is issued based on the request from the Management of the Company for the onward submission to monitoring agency in connection with the utilization of the proceeds from Initial Public Offer under the Issue of Capital and Disclosure Requirements Regulations and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For, R V D & Co.
Chartered Accountants
ICAI Firm Registration No: 143936W

R V D & Co.
FRN: 143936W
M.No.: 174550
City: Rajkot
Chartered Accountants

Kaushal V. Dave
(Partner)
Membership No: 174550
UDIN: 26174550LGPVMY1975

Date: July 30,2026
Place: Rajkot

Annexure B

Name of the issuer: Anlon Healthcare Limited

For quarter ended: June 30, 2026

(a) Deviation from the objects: Yes

(b) Range of Deviation: NA

Declaration:

We declare that this report is based on the format prescribed by the SEBI (ICDR) Regulations, 2018, We further declare that this report provides a true and fair view of the utilization of the issue proceeds.

We declare that we do not have any direct/indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship/interest while reporting the utilization of the issue proceeds by the issuer.

Yours faithfully,

For, R V D & Co.
Chartered Accountants
ICAI Firm Registration No: 143936W

R V D & Co.
FRN : 143936W
M.No. : 174550
City : Rajkot
Chartered Accountants

Kaushal V. Dave
(Partner)
Membership No: 174550
UDIN: 26174550LGPVMY1975

Date: July 30,2026
Place: Rajkot

RVD & Co.

1) **Issuer Details:**
Name of the issuer: Anlon healthcare Limited
Names of the promoter: Mr. Puntkumar Rameshbhai Rasadia
Industry/Sector to which it belongs: Pharmaceutical

2) **Issue Details:**
Issue period: August 26, 2025 to August 29, 2025
Type of issue (public/rights): Public
Type of specified securities: Equity
IPO Grading, if any: NA
Issue size (in Lacs): Rs.121.03

3) **Details of the arrangement made to ensure the monitoring of issue proceeds:**

Particulars	Reply (Yes/No/NA)	Comments of the Auditor
Whether all utilization is as per the disclosures in the Offer Document?	Yes	
Whether shareholder approval has beenobtained in case of material deviations from expenditures disclosed in the Offer Document?	NA	
Whether the means of finance for the disclosed objects of the issue haschanged?	No	
Is there any major deviation observedover the earlier monitoring agency reports?	No	
Whether all Government/statutory approvals related to the object(s) have been obtained?	No	
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	NA	
Are there any favorable events improving the viability of these object(s)?	No	
Are there any unfavorable events affecting the viability of the object(s)?	No	
Is there any other relevant information that may materially affect the decision making of the investors?	No	

RVD & Co. Chartered Accountants FRN : 143936W M.No. : 174550 City : Rajkot

4) **Details of object(s)s to be monitored:**

(i) **Cost of object(s)-**

Sr. No.	Item Head	Revised Cost	Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1	**Funding capital expenditure requirements for the expansion of our Manufacturing Facility and Inorganic growth and further upgradation**	3071.95	No Revision	No Comment	No Comment
2	**Full or part repayment and/or pre-payment of certain outstanding secured borrowing (term loan) availed by our Company**	500.00	No Revision	No Comment	No Comment
3	**Funding the Working capital requirement**	4,315.00	No Revision	No Comment	No Comment
4	**Offer Expense**	1,428.66	Transferring of Excess Fund Allocated to Offer Expenses to GCP	No Comment	No Comment
5	**General corporate purposes**	2,787.39			
6	**Total**	**12,103.00**			

(ii) **Progress in the object(s) –**

Object(S)	**Amount as per final offer document**	**Revised Cost**	**Amount utilized at the beginning of the reported quarter**	**Amount utilized during the reported quarter**	**Amount utilized at the end of the reported quarter**	**Total unutilized amount as at the end of the reported quarter**	**Reason for idle funds**	**Proposed course of actions**
Funding capital expenditure requirements for the expansion of our Manufacturing Facility	3,071.95	3,071.95	3,071.95	-	3,071.95			
Full or part repayment and/or pre-payment of certain outstanding secured borrowing (term loan) availed by our Company	500.00	500.00	500.00	-	500.00	-		
Funding the Working capital requirement	4,315.00	4,315.00	4,315.00	-	4,315.00	-		
Offer Expense	1,513.05	1,428.66	1,428.66	-	1,428.66	-		

R V D & Co.
FRN : 143936W
City : Rajkot
Chartered Accountants

"Level-6",Office No 604-605,Near AP Park, Opp Imperial Heights, Rajkot-360005
+91 6356 797 885 0281 - 2991685 office@cakda.in www.cakda.in

Object(S)	Amount as per final offer document	Revised Cost	Amount utilized at the beginning of the reported quarter	Amount utilized during the reported quarter	Amount utilized at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter	Reason for idle funds	Proposed course of actions
General corporate purposes	2,703.00	2,787.39	2,774.19	13.20	2,787.39	-		
Total	**12,103.00**	**12,103.00**	**12,089.80**	**13.20**	**12,103.00**	-		

(iii) **Deployment of unutilized IPO proceeds:**

S. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning (as at quarter end)	Return on Investment (%)	Market value as at the end of quarter (if the market value is not feasible, provide NAV/NRV/Book value of the same)
There is no unutilized balance of IPO Proceeding						

(iv) **Delay in implementation of the objects: Not Applicable**

(v) **Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:**

Sr. No.	Item heads	Amount in Lacs	Remarks
1	Meeting expenses incurred in ordinary business	13.20	Towards working capital
	Total Utilization in GCP	**13.20**	

.Note: As on the date of this certificate, all funds raised through the Initial Public Offering (IPO) have been fully utilized in accordance with the objects of the issue, and no unutilized IPO proceeds remain as on the date of this certificate.

R V D & Co. FRN: 143936W M. No.: 174... City: Rajkot Chartered Accountants